Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8IWU9

UPID:
TPH2_HUMAN

ALTERNATIVE NAMES:
Neuronal tryptophan hydroxylase; Tryptophan 5-monooxygenase 2

ALTERNATIVE UPACC:
Q8IWU9; A6NGA4; Q14CB0

BACKGROUND:
The protein Tryptophan 5-hydroxylase 2, with alternative names Neuronal tryptophan hydroxylase and Tryptophan 5-monooxygenase 2, is instrumental in the synthesis of serotonin. This enzyme's function is critical for the regulation of mood, appetite, and sleep, highlighting its importance in neural function and overall mental health.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Tryptophan 5-hydroxylase 2 could open doors to potential therapeutic strategies for Major depressive disorder and Attention deficit-hyperactivity disorder 7. These conditions, linked to serotonin production deficits, underscore the therapeutic potential of modulating this protein's activity to restore balance and improve patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.